web analytics

Vystar Corp. (OTC: VYST) Surges Higher as RxAir Gains Traction

0

Vystar Corp. (OTC: VYST) is surging upwards on heavy accumulation from investors and when a stock like VYST heats up, investors pay attention. VYST has a long history of explosive moves making a specular run in early 2019 from tiple zeroes to over $0.15 making many speculators rich along the way. The stock is  currently seeing higher highs and higher lows with a recent high of $.0724 last month. VYST boasts legions of shareholders who continue to bid the stock higher.

VYST is on the move as its newest and most exciting division RxAir gains traction. RxAir patented, ViraTech air purification technology has been proven to destroy greater than 99% of bacteria and viruses and reduce concentrations of odors and VOCs. Independently tested by EPA- and FDA-certified laboratories, the RxAir uses high-intensity germicidal UV lamps that destroy bacteria and viruses instead of just trapping them, setting it apart from ordinary air filtration units. Vystar recently said it has received cash deposits on pre-orders of approximately $1 million of RXAir products at retail since taking pre-orders on its RxAir.com website.

Vystar Corp. (OTC: VYST) is the owner and manufacturer of multiple brands of eco-friendly products for the home, office and medical sectors. The Company is the creator and exclusive owner of the innovative technology to produce Vytex Natural Rubber Latex “NRL”. Microcapdaily reported on Vystar as it acquired Rotmans Furniture and Carpet, the largest furniture and flooring store in New England.

Vystar most exciting new division is RXAIR which promotes a healthy lifestyle through the use of its innovative patented, ViraTech air purification technology. Independently tested by EPA- and FDA-certified laboratories, the RxAir has been proven to destroy greater than 99% of bacteria and viruses and reduce concentrations of odors and VOCs. The RxAir uses high-intensity germicidal UV lamps that destroy bacteria and viruses instead of just trapping them, setting it apart from ordinary air filtration units. Vystar recently said it has received cash deposits on pre-orders of approximately $1 million of RXAir products at retail since taking pre-orders on its RxAir.com website. Vystar Rx Air Rx3000 combines patented ViraTech™ germicidal UV-C light with a five-stage HEPA filtration to kill 99.97% of airborne viruses, bacteria and other contaminants. A single unit of th the Rx3000 can service a 1,500 – 3,000 sq. ft. area and it is used in hundreds of hospitals and healthcare facilities according to Vystar.

Vystar new RxAir400 is a smaller, consumer/small business-sized version of the industrial size Rx3000 FDA-certified Class II medical device UV light air purifier. Its patented kill chamber prolongs exposure of airborne pathogens to industrial-strength, high-intensity UV-C lights, recirculating an area’s air up to eight times per hour and continually inactivating pathogens to reduce exposure for occupants.  Vystar recently found a new manufacturer for the RxAir400 and said it anticipates receiving the first shipment of 10,000 RxAir400 units and replacement bulb cartridges from the manufacturer in approximately 45 days. Vystar also recently introducted RxAir400 UV-C Light Germicidal Air Purifier Extended Life UV Bulb. RxAir®400 Germicidal Ultraviolet (UV-C) light air purification systems offers new features and options that will make it easier to treat airborne pathogens wherever you go indoors.

To Find out the inside Scoop on VYST Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

VYST

Bryan Stone, MD, Internal Medicine and Nephrology, and Chief of Medicine for Desert Regional Medical Center stated: “A main advantage of RxAir is that it can operate safely in occupied spaces to continuously process the air up to eight times per hour, inactivating or killing the pathogens expelled as people talk, breathe, cough, sneeze or sing to help reduce risk of exposure for those in the room. When near people who aren’t wearing masks and may be asymptomatic, it is reassuring to have RxAir treating pathogens they may be expelling. RxAir400’s ViraTech technology is one of the few UV light air purification technologies proven in EPA- and FDA-certified laboratory testing to inactivate more than 99.9% of airborne viruses (including multiple coronavirus strains), bacteria and other pathogens that cause pneumonia, influenza, MRSA (staph), streptococcus (strep throat), whooping cough, tuberculosis (TB), common cold, measles and a myriad of other antibiotic-resistant and viral infections,” Dr. Stone explained. “Hospitals and healthcare facilities have been using ultraviolet germicidal irradiation (UVGI) with UV-C light for airborne infection control for decades because it is so effective. It also reduces concentration of volatile organic compounds and odors as well as air pollution linked to sleep disorders.”

MicroCapDaily first reported on VYST back on January 14, 2019 as the stock was embarking on its historic run, stating at the time: “Vystar Corp. (OTC: VYST) is making a powerful move up off its $0.0005 low’s to recent highs near a penny. The stock has quickly attracted a large shareholder base which has propelled VYST to the OTCBB top traded.

We have a Monster Pick Coming. Subscribe Right Now!

Currently heating up and running up the charts Vystar had a memorable 2019 reporting 13,685,872 in revenues according to its most recent 10k. VYST is on the move as its newest and most exciting division RxAir gains traction. RxAir patented, ViraTech air purification technology has been proven to destroy greater than 99% of bacteria and viruses and reduce concentrations of odors and VOCs. Independently tested by EPA- and FDA-certified laboratories, the RxAir uses high-intensity germicidal UV lamps that destroy bacteria and viruses instead of just trapping them, setting it apart from ordinary air filtration units. Vystar recently said it has received cash deposits on pre-orders of approximately $1 million of RXAir products at retail since taking pre-orders on its RxAir.com website. VYST boasts legions of shareholders who continue to bid the stock higher; when a stock like VYST heats up, investors pay attention; Microcapdaily covered VYST when it made its historic run back in early 2019 from tiple zeroes to over $0.15. We will be updating on VYST when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with VYST.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in VYST either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.